GomesBR, BocchiEA. Quality of Life in Heart Failure: An Important Goal in Treatment. Arq. Bras. Cardiol. 2020;114(1):33-4.
Gomes,Brenno Rizerio; Bocchi,Edimar Alcides. Quality of Life in Heart Failure: An Important Goal in Treatment. Arq. Bras. Cardiol., v. 114, n. 1, p. 33-34, Jan. 2020.
Gomes,B.R., & Bocchi,E.A. (2020). Quality of Life in Heart Failure: An Important Goal in Treatment. Arq. Bras. Cardiol.,114(1), 33-34.
Gomes,Brenno Rizerio and Bocchi,Edimar Alcides. Quality of Life in Heart Failure: An Important Goal in Treatment. Arq. Bras. Cardiol. [online]. 2020, vol. 114, n. 1, [cited 2025-09-06], pp.33-34. Available from: <https://abccardiol.org/en/short-editorial/quality-of-life-in-heart-failure-an-important-goal-in-treatment/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.